vs
PHIBRO ANIMAL HEALTH CORP（PAHC）与Rapid7, Inc.（RPD）财务数据对比。点击上方公司名可切换其他公司
PHIBRO ANIMAL HEALTH CORP的季度营收约是Rapid7, Inc.的1.7倍（$373.9M vs $217.4M），PHIBRO ANIMAL HEALTH CORP净利率更高（7.3% vs 1.4%，领先5.9%），PHIBRO ANIMAL HEALTH CORP同比增速更快（20.9% vs 0.5%），Rapid7, Inc.自由现金流更多（$36.4M vs $8.3M），过去两年PHIBRO ANIMAL HEALTH CORP的营收复合增速更高（19.2% vs 3.0%）
菲宝罗动物保健公司是一家美国动物健康与矿物质营养企业，主营产品涵盖抗菌药、抗球虫药、驱虫药，以及畜禽营养补充剂、疫苗等。公司下设矿物质营养、功能材料、动物健康三大业务板块，收入主要来源于上述板块，业务遍及美国、拉美、加拿大、欧洲、中东、非洲及亚太地区。
Rapid7是全球领先的网络安全企业，提供漏洞管理、威胁检测与响应、云安全、安全分析等全系列安全解决方案，服务全球科技、医疗、金融、制造等行业的各类规模企业及公共部门客户，助力客户高效识别、应对和缓解网络安全风险。
PAHC vs RPD — 直观对比
营收规模更大
PAHC
是对方的1.7倍
$217.4M
营收增速更快
PAHC
高出20.4%
0.5%
净利率更高
PAHC
高出5.9%
1.4%
自由现金流更多
RPD
多$28.2M
$8.3M
两年增速更快
PAHC
近两年复合增速
3.0%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $373.9M | $217.4M |
| 净利润 | $27.5M | $3.1M |
| 毛利率 | 35.5% | 68.9% |
| 营业利润率 | 13.5% | 1.0% |
| 净利率 | 7.3% | 1.4% |
| 营收同比 | 20.9% | 0.5% |
| 净利润同比 | 762.1% | 44.1% |
| 每股收益（稀释后） | $0.67 | $0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PAHCRPD
| Q4 25 | $373.9M | $217.4M | ||
| Q3 25 | $363.9M | $218.0M | ||
| Q2 25 | $378.7M | $214.2M | ||
| Q1 25 | $347.8M | $210.3M | ||
| Q4 24 | $309.3M | $216.3M | ||
| Q3 24 | $260.4M | $214.7M | ||
| Q2 24 | $273.2M | $208.0M | ||
| Q1 24 | $263.2M | $205.1M |
净利润PAHCRPD
| Q4 25 | $27.5M | $3.1M | ||
| Q3 25 | $26.5M | $9.8M | ||
| Q2 25 | $17.2M | $8.3M | ||
| Q1 25 | $20.9M | $2.1M | ||
| Q4 24 | $3.2M | $2.2M | ||
| Q3 24 | $7.0M | $15.4M | ||
| Q2 24 | $752.0K | $6.5M | ||
| Q1 24 | $8.4M | $1.4M |
毛利率PAHCRPD
| Q4 25 | 35.5% | 68.9% | ||
| Q3 25 | 32.9% | 70.2% | ||
| Q2 25 | 29.0% | 70.6% | ||
| Q1 25 | 30.1% | 71.7% | ||
| Q4 24 | 32.9% | 69.5% | ||
| Q3 24 | 32.1% | 70.6% | ||
| Q2 24 | 31.9% | 70.7% | ||
| Q1 24 | 30.2% | 70.3% |
营业利润率PAHCRPD
| Q4 25 | 13.5% | 1.0% | ||
| Q3 25 | 14.1% | 2.7% | ||
| Q2 25 | 8.9% | 1.6% | ||
| Q1 25 | 9.6% | -0.0% | ||
| Q4 24 | 8.3% | 3.4% | ||
| Q3 24 | 6.8% | 6.0% | ||
| Q2 24 | 6.7% | 2.5% | ||
| Q1 24 | 7.6% | 4.7% |
净利率PAHCRPD
| Q4 25 | 7.3% | 1.4% | ||
| Q3 25 | 7.3% | 4.5% | ||
| Q2 25 | 4.5% | 3.9% | ||
| Q1 25 | 6.0% | 1.0% | ||
| Q4 24 | 1.0% | 1.0% | ||
| Q3 24 | 2.7% | 7.2% | ||
| Q2 24 | 0.3% | 3.1% | ||
| Q1 24 | 3.2% | 0.7% |
每股收益（稀释后）PAHCRPD
| Q4 25 | $0.67 | $0.05 | ||
| Q3 25 | $0.65 | $0.15 | ||
| Q2 25 | $0.43 | $0.13 | ||
| Q1 25 | $0.51 | $0.03 | ||
| Q4 24 | $0.08 | $0.08 | ||
| Q3 24 | $0.17 | $0.21 | ||
| Q2 24 | $0.02 | $0.09 | ||
| Q1 24 | $0.21 | $0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $74.5M | $474.7M |
| 总债务越低越好 | $624.2M | — |
| 股东权益账面价值 | $332.4M | $154.7M |
| 总资产 | $1.4B | $1.7B |
| 负债/权益比越低杠杆越低 | 1.88× | — |
8季度趋势，按日历期对齐
现金及短期投资PAHCRPD
| Q4 25 | $74.5M | $474.7M | ||
| Q3 25 | $85.3M | $407.1M | ||
| Q2 25 | $77.0M | $511.7M | ||
| Q1 25 | $70.4M | $493.5M | ||
| Q4 24 | $67.1M | $521.7M | ||
| Q3 24 | $89.8M | $443.7M | ||
| Q2 24 | $114.6M | $442.6M | ||
| Q1 24 | $98.7M | $411.7M |
总债务PAHCRPD
| Q4 25 | $624.2M | — | ||
| Q3 25 | $628.0M | — | ||
| Q2 25 | $631.7M | — | ||
| Q1 25 | $635.4M | — | ||
| Q4 24 | $639.1M | — | ||
| Q3 24 | $295.2M | — | ||
| Q2 24 | $312.1M | — | ||
| Q1 24 | — | — |
股东权益PAHCRPD
| Q4 25 | $332.4M | $154.7M | ||
| Q3 25 | $311.7M | $127.2M | ||
| Q2 25 | $285.7M | $90.4M | ||
| Q1 25 | $266.0M | $52.7M | ||
| Q4 24 | $246.8M | $17.7M | ||
| Q3 24 | $258.5M | $-5.1M | ||
| Q2 24 | $256.6M | $-52.6M | ||
| Q1 24 | $270.1M | $-86.4M |
总资产PAHCRPD
| Q4 25 | $1.4B | $1.7B | ||
| Q3 25 | $1.4B | $1.7B | ||
| Q2 25 | $1.4B | $1.6B | ||
| Q1 25 | $1.3B | $1.6B | ||
| Q4 24 | $1.3B | $1.7B | ||
| Q3 24 | $966.3M | $1.6B | ||
| Q2 24 | $982.2M | $1.5B | ||
| Q1 24 | $979.0M | $1.5B |
负债/权益比PAHCRPD
| Q4 25 | 1.88× | — | ||
| Q3 25 | 2.01× | — | ||
| Q2 25 | 2.21× | — | ||
| Q1 25 | 2.39× | — | ||
| Q4 24 | 2.59× | — | ||
| Q3 24 | 1.14× | — | ||
| Q2 24 | 1.22× | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $19.4M | $37.6M |
| 自由现金流经营现金流 - 资本支出 | $8.3M | $36.4M |
| 自由现金流率自由现金流/营收 | 2.2% | 16.8% |
| 资本支出强度资本支出/营收 | 3.0% | 0.5% |
| 现金转化率经营现金流/净利润 | 0.70× | 12.01× |
| 过去12个月自由现金流最近4个季度 | $47.3M | $146.2M |
8季度趋势，按日历期对齐
经营现金流PAHCRPD
| Q4 25 | $19.4M | $37.6M | ||
| Q3 25 | $9.3M | $39.0M | ||
| Q2 25 | $21.3M | $47.5M | ||
| Q1 25 | $43.2M | $29.8M | ||
| Q4 24 | $3.1M | $63.8M | ||
| Q3 24 | $12.6M | $44.0M | ||
| Q2 24 | $28.4M | $32.9M | ||
| Q1 24 | $11.4M | $31.1M |
自由现金流PAHCRPD
| Q4 25 | $8.3M | $36.4M | ||
| Q3 25 | $-4.5M | $34.8M | ||
| Q2 25 | $8.1M | $46.6M | ||
| Q1 25 | $35.4M | $28.4M | ||
| Q4 24 | $-4.7M | $62.6M | ||
| Q3 24 | $3.0M | $42.6M | ||
| Q2 24 | $15.4M | $32.6M | ||
| Q1 24 | $1.7M | $30.4M |
自由现金流率PAHCRPD
| Q4 25 | 2.2% | 16.8% | ||
| Q3 25 | -1.2% | 16.0% | ||
| Q2 25 | 2.1% | 21.8% | ||
| Q1 25 | 10.2% | 13.5% | ||
| Q4 24 | -1.5% | 28.9% | ||
| Q3 24 | 1.2% | 19.9% | ||
| Q2 24 | 5.6% | 15.7% | ||
| Q1 24 | 0.6% | 14.8% |
资本支出强度PAHCRPD
| Q4 25 | 3.0% | 0.5% | ||
| Q3 25 | 3.8% | 1.9% | ||
| Q2 25 | 3.5% | 0.4% | ||
| Q1 25 | 2.2% | 0.6% | ||
| Q4 24 | 2.5% | 0.5% | ||
| Q3 24 | 3.7% | 0.6% | ||
| Q2 24 | 4.8% | 0.1% | ||
| Q1 24 | 3.7% | 0.3% |
现金转化率PAHCRPD
| Q4 25 | 0.70× | 12.01× | ||
| Q3 25 | 0.35× | 3.97× | ||
| Q2 25 | 1.24× | 5.70× | ||
| Q1 25 | 2.07× | 14.14× | ||
| Q4 24 | 0.97× | 29.36× | ||
| Q3 24 | 1.81× | 2.85× | ||
| Q2 24 | 37.80× | 5.03× | ||
| Q1 24 | 1.36× | 22.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PAHC
| Medicated Feed Additives And Others | $202.1M | 54% |
| Mineral Nutrition | $68.9M | 18% |
| Nutritional Specialties | $50.2M | 13% |
| Vaccines | $37.6M | 10% |
| Performance Products | $15.0M | 4% |
RPD
| Products | $209.1M | 96% |
| Services | $8.2M | 4% |
